JP2007536260A5 - - Google Patents

Download PDF

Info

Publication number
JP2007536260A5
JP2007536260A5 JP2007511623A JP2007511623A JP2007536260A5 JP 2007536260 A5 JP2007536260 A5 JP 2007536260A5 JP 2007511623 A JP2007511623 A JP 2007511623A JP 2007511623 A JP2007511623 A JP 2007511623A JP 2007536260 A5 JP2007536260 A5 JP 2007536260A5
Authority
JP
Japan
Prior art keywords
sequence
genbank
seq
positions
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007511623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007536260A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/015799 external-priority patent/WO2005107793A2/en
Publication of JP2007536260A publication Critical patent/JP2007536260A/ja
Publication of JP2007536260A5 publication Critical patent/JP2007536260A5/ja
Withdrawn legal-status Critical Current

Links

JP2007511623A 2004-05-06 2005-05-06 虚血性および腎毒性障害の軽減および改善用ngal Withdrawn JP2007536260A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56864504P 2004-05-06 2004-05-06
US61556604P 2004-10-01 2004-10-01
PCT/US2005/015799 WO2005107793A2 (en) 2004-05-06 2005-05-06 Ngal for reduction and amelioration of ischemic and nephrotoxic injuries

Publications (2)

Publication Number Publication Date
JP2007536260A JP2007536260A (ja) 2007-12-13
JP2007536260A5 true JP2007536260A5 (https=) 2008-03-06

Family

ID=35320735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007511623A Withdrawn JP2007536260A (ja) 2004-05-06 2005-05-06 虚血性および腎毒性障害の軽減および改善用ngal

Country Status (6)

Country Link
US (5) US7776824B2 (https=)
EP (2) EP1750500B1 (https=)
JP (1) JP2007536260A (https=)
AU (1) AU2005240190C1 (https=)
CA (1) CA2565701A1 (https=)
WO (1) WO2005107793A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
AU2005288522B2 (en) * 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
ES2818028T3 (es) * 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
US20090305963A1 (en) * 2005-01-19 2009-12-10 Sukhatme Vikas P Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
JP4865377B2 (ja) 2006-03-28 2012-02-01 国立大学法人 新潟大学 ヒトメガリンの測定方法
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
WO2008017306A1 (en) * 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
EP2095106B1 (en) * 2006-11-14 2013-03-20 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
WO2008060607A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
JP5128828B2 (ja) * 2007-02-16 2013-01-23 月桂冠株式会社 抗炎症剤及び抗酸化剤
WO2008113363A1 (en) 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
WO2009001359A2 (en) * 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
EP2257813A4 (en) 2008-03-12 2011-11-02 Univ Columbia NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
US20100122355A1 (en) * 2008-07-16 2010-05-13 Neal Paragas Transgenic Reporter Mouse and Method for Use
EP2330897A4 (en) * 2008-09-18 2013-11-27 Univ Columbia NGAL-BINDING SIDEROPHORES AND THEIR USE FOR THE TREATMENT OF IRON DEFICIENCY AND IRON SURPLUS
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
KR101939964B1 (ko) * 2008-11-21 2019-01-18 퓨처 메디칼 다이아그노스틱스 코 엘티디 급성 신장 손상의 발견 또는 감시 방법, 장치 및 키트
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
US20100233740A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
JP5424702B2 (ja) 2009-04-27 2014-02-26 国立大学法人 新潟大学 尿中ヒトメガリンを測定することを含む腎疾患検出方法
US8628930B2 (en) 2009-04-27 2014-01-14 Niigata University Use of megalin in urine as marker for detecting renal disorder
EP2292284B1 (en) * 2009-09-04 2014-02-26 B. Braun Avitum AG Kidney substitution treatment machine
CN102844044B (zh) 2010-02-04 2016-10-26 摩尔弗泰克有限公司 氯毒素多肽和结合物及其应用
WO2011140554A1 (en) * 2010-05-07 2011-11-10 The Trustees Of Columbia University In The City Of New York Ngal and urinary tract infection
EP3165533B1 (en) 2010-05-11 2020-04-08 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates and methods for their use
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
WO2012042061A1 (en) * 2010-10-01 2012-04-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the progression and treating a chronic kidney disease in a patient
EP2697389A4 (en) * 2011-04-11 2014-09-10 Univ Columbia ABOUT OSTEOBLASTEN EXPRESSED LIPOCALIN 2 FOR THE ADJUSTMENT OF GLUCOSE COMPOUND CHANGES
WO2012167092A2 (en) * 2011-06-03 2012-12-06 The Regents Of The University Of Colorado, A Body Corporate Uses of and methods of treatment with cystathionine
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
CA2913029A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EP3200582B1 (en) 2014-09-29 2023-11-15 Fred Hutchinson Cancer Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
JP5866053B1 (ja) * 2014-12-15 2016-02-17 株式会社ファンケル 皮膚粘弾性のマーカー及びその利用
WO2017027858A1 (en) 2015-08-12 2017-02-16 The Trustees Of Columbia University In The City Of New York Methods of treating volume depletion and kidney injury
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
EP3383415B1 (en) 2015-12-01 2021-03-31 Cornell University Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease
US11220541B2 (en) 2015-12-22 2022-01-11 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
TWI581802B (zh) * 2015-12-23 2017-05-11 國立臺灣師範大學 嗜中性白血球膠原蛋白質酶相關疏水性蛋白質之製藥用途
EP3184116B1 (en) * 2015-12-23 2020-09-16 National Taiwan Normal University Neutrophil gelatinase-associated lipocalin for use in prevention or treatment of polycystic kidney disease
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
IL271564B2 (en) * 2017-06-23 2024-06-01 Aki Therapeutics Aps Compositions for the prevention and treatment of acute renal injury
US11298564B2 (en) 2020-03-10 2022-04-12 Dennis M. Anderson Medical, surgical and patient lighting apparatus, system, method and controls with pathogen killing electromagnetic radiation
CN113075371B (zh) * 2021-03-22 2022-11-18 重庆医药高等专科学校 一种药物崩解仪

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100251594B1 (ko) * 1995-04-12 2000-06-01 알카 쿠보넨 치근막 질환의 진단과 이의 진행위험을 예견하는 방법과 이에 사용되는 테스트 키트
ES2258793T5 (es) 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
AUPP784398A0 (en) 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US6114123A (en) 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
AU2003247303A1 (en) 2002-07-17 2004-02-02 Index Pharmaceuticals Ab Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
DE602004022150D1 (de) 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury

Similar Documents

Publication Publication Date Title
JP2007536260A5 (https=)
JP2004538039A5 (https=)
JP2010524959A5 (https=)
JP2008245635A5 (https=)
JP2003515323A5 (https=)
JP2007518723A5 (https=)
JP2009542225A5 (https=)
JP2005520490A5 (https=)
JP2009530811A5 (https=)
JP2007075118A5 (https=)
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
JP2003160581A5 (https=)
JP2007119504A5 (https=)
JP2003507417A5 (https=)
JP2007508527A5 (https=)
JP2008501649A5 (https=)
JP2006522692A5 (https=)
JP2006505391A5 (https=)
JP2005518781A5 (https=)
JP2005534326A5 (https=)
JP2005536763A5 (https=)
JP2007523200A5 (https=)
DE102005011421A8 (de) Bestimmung von kurzkettiger SRL-Alkoholdehydrogenase (DHRS4) als Biomarker für Entzündungen und Infektionen
JP2009532334A5 (https=)
JP2008508340A5 (https=)